ARTICLE | Company News
ID Biomedical, Intellivax deal
May 21, 2001 7:00 AM UTC
IDBE completed its stock acquisition of Intellivax, a developer of influenza vaccines, for 4 million shares of IDBE common stock, valued at $15.8 million, using IDBE's Friday NASDAQ close of $3.95 (se...